| 2163 in JNK-knockout mice was associated with increased expression of the cell senescence marker p16 INK4a in the synovium and cartilage. Despite the negative findings we reported from our study, Dr. Xu and Ms Huang questioned whether JNK signaling might still be a valuable target to treat OA. They noted conflicting results from previously published in vitro studies that demonstrated that JNK inhibition reduced catabolic and proinflammatory signaling, as well as findings from a prior study indicating that JNK2 deletion reduced cartilage damage in the DMM model. At issue is the very complex nature of signal transduction pathways, such as the JNK pathway, that serve multiple homeostatic and potentially pathologic functions. In a previous study (1), our group noted that Col2Cre-mediated conditionaldouble-knockout of JNK1/2 in type II collagen-expressing cells resulted in a severe scoliotic phenotype, indicating that JNK signaling is necessary for normal spinal development. This finding was supported by a report of a similar scoliotic phenotype in mice in which c-Jun, which is activated by JNK, was knocked out (2). In our present study, the finding of increased cell senescence in JNK-knockout mice was surprising; however, it was supported by findings of previous studies in non-joint tissues (3,4). A second issue is that in vitro experiments using a single cell type in culture, such as those with results suggesting that JNK inhibition could inhibit catabolic pathways involved in OA, do not necessarily translate to the complexity of the in vivo environment. A particular issue in many studies of JNK signaling has been the use of JNK inhibitors, such as SP600125, that have been found to lack specificity and have off-target effects at concentrations used to inhibit JNK (5). A third issue is the lack of replication of findings of in vivo studies in mice, even when the same mouse strain from the same source is used. One important consideration is the number of mice in each experimental group. In human studies, positive results in early-phase studies using a small number of participants are often not replicated in larger clinical trials. In the report by Ismail et al (6) in which the authors noted less cartilage damage after DMM surgery in JNK-knockout mice, only 4-6 mice per experimental group were studied, whereas we studied 15 mice per experimental group. We agree that further study of the role of JNK signaling in articular joints is needed. In particular, we are interested in determining the mechanism by which JNK loss leads to cell senescence. However, we would argue that the preclinical evidence to date does not support JNK inhibition as a safe and effective intervention for OA in humans.